Neurocognitive functioning of individuals with Schizophrenia: Using and not using drugs

Schizophrenia Bulletin

Volumn 40, Issue 4, 2014, Pages 856-867

  Bahorik, Amber L ^a,b   Newhill, Christina E ^a   Eack, Shaun M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

cannabis; cognitive function; comorbidity; illicit drugs; psychosis; schizophrenia

Indexed keywords

CANNABIS; COCAINE; METHAMPHETAMINE;

ADULT; AGE; ALERTNESS; ARTICLE; CANNABIS USE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HAIR ANALYSIS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SUBSTANCE USE; TASK PERFORMANCE; VERBAL MEMORY; WORKING MEMORY; CANNABIS SMOKING; CHEMISTRY; COCAINE-RELATED DISORDERS; COGNITIVE DEFECT; DRUG ABUSE; HAIR; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ADULT; AMPHETAMINE-RELATED DISORDERS; COCAINE-RELATED DISORDERS; COGNITION; COGNITION DISORDERS; FEMALE; HAIR; HUMANS; MALE; MARIJUANA SMOKING; METHAMPHETAMINE; MIDDLE AGED; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84902585008     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt099     Document Type: Article

References (102)

1. Reimherr F, Swartz M, Olsen J. Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. In: Stroup ST, Liberman JA, eds. Antipsychotic Trials in Schizophrenia. New York, NY: Cambridge University Press; 2010: 189-206.
2. Keefe RS. Neurocognition. In: Stroup ST, Liberman JA, eds. Antipsychotic Trials in Schizophrenia. New York, NY: Cambridge University Press; 2010: 189-206.
3. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav. 2012;37:11-24.
4. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
5. Volkow ND. Substance use disorders in schizophrenia-clinical implications of comorbidity. Schizophr Bull. 2009;35:469-472.
6. Swartz MS, Wagner HR, Swanson J W, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis. 2006;194:164-172.
7. Degenhardt L, Hall W. The association between psychosis and problematical drug use among Australian adults: fnd-ings from the National Survey of Mental Health and Well-Being. Psychol Med. 2001;31:659-668.
8. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002;62:743-755.
9. Kavanagh DJ, Waghorn G, Jenner L, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res. 2004;66:115-124.
10. Keefe RS, Eesley CE, Poe M P. Defning a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005;57:688-691.
11. Palmer BW, Heaton RK, Paulsen JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997;11:437-446.
12. DeRosse AK, Burdick K, Lencz T, Malhotra A. Cannabis use disorders in schizophrenia: effects in cognition and symptoms. Schizophr Res. 2010;120:95-100.
13. Lø berg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci. 2009; 3: 53.
14. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41-51.
15. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999;156:1328-1335.
16. Reichenberg A, Weiser M, Rapp MA, et al. Elaboration on premorbid intellectual performance in schizophrenia: pre-morbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry. 2005;62:1297-1304.
17. Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry. 2002;159:1183-1189.
18. Dixon L, Haas G, Weiden P, Sweeney J, Frances A. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull. 1990;16:69-79.
19. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35 (suppl):S93-100.
20. Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL Jr, Davis JM, Lewis DA. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995;152:856-861.
21. Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner HR, Burns BJ. Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. Am J Psychiatry. 1998;155:226-231.
22. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res. 1996;20:145-151.
23. Swanson J, Estroff S, Swartz M, et al. Violence and severe mental disorder in clinical and community populations: the effects of psychotic symptoms, comorbidity, and lack of treatment. Psychiatry. 1997;60:1-22.
24. Goodman LA, Salyers MP, Mueser KT, et al.; 5 Site Health and Risk Study Research Committee. Recent victimization in women and men with severe mental illness: prevalence and correlates. J Trauma Stress. 2001;14:615-632.
25. Carey KB, Carey MP, Simons JS. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J Nerv Ment Dis. 2003;191:300-308.
26. Herman M. Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. Int J Ment Health Nurs. 2004;13: 282-291.
27. Løberg EM, Jøgensen HA, Hugdahl K. The effects of previous drug abuse on neurocognitive function in schizophrenia. J Int Neuropsychol Soc. 2003;9:172.
28. Løberg EM, Hugdahl K, Jøgensen HA. Lower neurocogni-tive vulnerability in schizophrenia with a history of cannabis abuse? Schizophr Res. 2008;98:73.
29. Thoma P, Wiebel B, Daum I. Response inhibition and cognitive fexibility in schizophrenia with and without comorbid substance use disorder. Schizophr Res. 2007;92:168-180.
30. Ruiz-Veguilla M, Gurpegui M, Barrigón ML, et al. Fewer neurological soft signs among frst episode psychosis patients with heavy cannabis use. Schizophr Res. 2009;107:158-164.
31. Joyal CC, Hallé P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res. 2003;63: 297-299.
32. Potvin S, Briand C, Prouteau A, et al. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn. 2005;59:38-42.
33. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to frst onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res. 2005;75:135-137.
34. McCleery A, Addington J, Addington D. Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophr Res. 2006;88:187-191.
35. Schnell T, Koethe D, Daumann J, Gouzoulis-Mayfrank E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berl). 2009;205: 45-52.
36. Jockers-Scherübl MC, Wolf T, Radzei N, et al. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1054-1063.
37. Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr Res. 2008;100: 242-251.
38. Rabin RA, Zakzanis KK, George T P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res. 2011;128:111-116.
39. Yücel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing fndings and new data in a frst-episode sample. Schizophr Bull. 2012;38:316-330.
40. Addington J, Addington D. Substance abuse and cognitive functioning in schizophrenia. J Psychiatry Neurosci. 1997;22:99-104.
41. Scholes KE, Martin-Iverson MT. Cannabis use and neu-ropsychological performance in healthy individuals and patients with schizophrenia. Psychol Med. 2009;17:1-12.
42. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci. 2003;28:48-54.
43. Sevy S, Burdick KE, Visweswaraiah H, et al. Iowa gambling task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res. 2007;92:74-84.
44. Mata I, Rodríguez-Sánchez JM, Pelayo-Terán JM, et al. Cannabis abuse is associated with decision-making impairment among frst-episode patients with schizophrenia-spectrum psychosis. Psychol Med. 2008;38:1257-1266.
45. Ringen PA, Vaskinn A, Sundet K, et al. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol Med. 2010;40:1337-1347.
46. Serper MR, Bergman A, Copersino ML, Chou JC, Richarme D, Cancro R. Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res. 2000;93:21-32.
47. Serper MR, Copersino ML, Richarme D, Vadhan N, Cancro R. Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. J Subst Abuse. 2000;11:205-213.
48. Sevy S, Kay SR, Opler LA, van Praag HM. Signifcance of cocaine history in schizophrenia. J Nerv Ment Dis. 1990;178:642-648.
49. D'Souza DC, Ranganathan M, Braley G, et al. Blunted psychotomimetic and amnestic effects of delta-9-tet-rahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008;33:2505-2516.
50. Hoff AL, Riordan H, Morris L, et al. Effects of crack cocaine on neurocognitive function. Psychiatry Res. 1996;60:167-176.
51. Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, Ling W. Cognitive performance of current methampheta-mine and cocaine abusers. J Addict Dis. 2002;21:61-74.
52. Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010;36:1115-1130.
53. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet. 2007;363:1579-1588.
54. Kirkpatrick B, Amador XF, Flaum M, et al. The defcit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res. 1996;20:69-77.
55. Salyers MP, Mueser KT. Social functioning, psychopa-thology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res. 2001;48:109-123.
56. Schanda H, Földes P, Topitz A, Fliedl R, Knecht G. Premorbid adjustment of schizophrenic criminal offenders. Acta Psychiatr Scand. 1992;86:121-126.
57. Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353: 1209-1223.
58. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neu-rocognitive defcits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31:2033-2046.
59. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15-31.
60. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for Axes I and II DSM-IV Disorders-Patient Edition (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
61. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301-307.
62. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213.
63. Heaton RK, Chelune GJ, Taley JL, Kay GG, Curtiss G. Wisconsin Cart Sorting Test Manual: Revised and Expanded. Odessa, FL: Psychological Assessment Resources; 1993.
64. Wechsler D. Wechsler Intelligence Scale for Children. 3rd ed. San Antonio, TX: Psychological Corporation; 1991.
65. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry. 1997;54:159-165.
66. Lafeyette Instrument Company. Grooved Pegboard Instruction Manual (Model 32025). Lafayette, IN: Lafayette Instrument Company; 1989.
67. Wechsler D. WAIS-R Manual: Wechsler Adult Intelligence Scale-Revised. New York, NY: Psychological Corporation; 1981.
68. Benton AL, Hamscher K. Multilingual Aphasia Examination Manual (Revised). Iowa City, Iowa: University of Iowa; 1978.
69. Brandt J. The Hopkins Verbal Learning Test: Development of a new verbal memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125-142.
70. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New fndings about sustained attention in normal families. Psychiatry Res. 1988;26:223-238.
71. Baumgartner W, Hill V, Blahd W. Hair analysis for drug of abuse. J Forensic Sci. 1989;34:1433-1453.
72. Allgood CC, Sniegoski LT, Welch MJ. The analysis of human hair for drugs of abuse: Proceedings of the 39th ASMS Conference on MASS Spectrometry and Allied Topics, Nashville, TN, May 19-24; 1991.
73. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta. 2006;370:17-49.
74. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
75. Guy W. ECDEU Assessment Manual for Psychopharma-cology-Revised. Clinical Global Impressions. Rockville, MD: National Institute of Mental Health; 1976.
76. Dickerson F, Kirkpatrick B, Boronow J, Stallings C, Origoni A, Yolken R. Defcit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull. 2006;32:396-400.
77. Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Case identifcation and stability of the defcit syndrome of schizophrenia. Psychiatry Res. 1993;47:47-56.
78. Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Depressive symptoms and the defcit syndrome of schizophrenia. J Nerv Ment Dis. 1994;182:452-455.
79. Tek C, Kirkpatrick B, Buchanan RW. A fve-year followup study of defcit and nondefcit schizophrenia. Schizophr Res. 2001;49:253-260.
80. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Defcit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119-123.
81. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis. 1992;180:723-728.
82. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. Strategies for switching from conventional antipsy-chotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000;61:833-840.
83. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21:14-20.
84. Haro JM, Kamath SA, Ochoa S. The Clinical Global Impression-Schizophrenia Scale: a simple instrument to measure diversity of symptoms present in schizophrenia. Acta Psychiatr Scand. 2003;107:16-23.
85. Woods S W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64: 663-667.
86. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24:1-10.
87. Hochberg Y. A sharper Bonferroni procedure for multiple tests of signifcance. Biometrika. 1998;75:800-803.
88. R Development Core Team. R: A Language and Environ ment for Statistical Computing. (Version 2.15.0) Computer Software. Vienna, Austria: R Foundation for Statistical Computing; 2012. http://softwaretopic.informer.com/development- core-team-2009/. Accessed December 22, 2012.
89. Bates DM, Maechler M. lme4: Linear Mixed-effects Models Using S4 Classes. R package version 0.999375-32; 2009. http://cran.r-project.org/web/packages/ lme4/lme4.pdf. Accessed December 22, 2012.
90. Schiffer B, Müller BW, Scherbaum N, et al. Impulsivity-related brain volume defcits in schizophrenia-addiction comorbidity. Brain. 2010;133:3093-3103.
91. D'Souza DC, Cho HS, Perry EB, Krystal JH. Cannabinoid "model" psychosis, dopamine-cannabinoid interactions and implications for schizophrenia. In: Castle D and Murray R, eds. Marijuana and Madness. Cambridge: Cambridge University Press; 2004: 142-165.
92. Beatty WW, Katzung VM, Moreland VJ, Nixon SJ. Neuropsychological performance of recently abstinent alcoholics and cocaine abusers. Drug Alcohol Depend. 1995;37:247-253.
93. van Gorp WG, Wilkins JN, Hinkin CH, et al. Declarative and procedural memory functioning in abstinent cocaine abusers. Arch Gen Psychiatry. 1999;56:85-89.
94. Mittenberg W, Motta S. Effects of chronic cocaine abuse on memory and learning. Arch Clin Neuropsychol. 1993;8:477-483.
95. Mieczkowski T, Barzelay D, Gropper B, Wish E. Concordance of three measures of cocaine use in an arrestee population: hair, urine, and self-report. J Psychoactive Drugs. 1991;23:241-249.
96. Bahorik AL, Newhill CE, Queen CC, Eack SM. Underreporting of drug use among individuals with schizophrenia: prevalence and predictors. Psychol Med. 2013;doi:10.1017/S0033291713000548.
97. Eack SM, Greenwald DP, Hogarty SS, et al. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv. 2009;60:1468-1476.
98. Hogarty GE, Flesher S, Ulrich R, et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry. 2004;61:866-876.
99. Magura S, Freeman RC, Siddiqi Q, Lipton DS. The validity of hair analysis for detecting cocaine and heroin use among addicts. Int J Addict. 1992;27:51-69.
100. Kline J, Ng SK, Schittini M, Levin B, Susser M. Cocaine use during pregnancy: sensitive detection by hair assay. Am J Public Health. 1997;87:352-358.
101. Mieczkowski T, Newel R. Comparing hair and urine assays for cocaine marijuana. Fed Probat. 1993;57:59-66.
102. Swartz MS, Swanson J W, Hannon MJ. Detection of illicit substance use among persons with schizophrenia by radioim-munoassay of hair. Psychiatr Serv. 2003;54:891-895.